According to data from Benzinga Pro, during Q3, Blueprint Medicines's BPMC reported sales totaled $65.98 million. Despite a 16.62% increase in earnings, the company posted a loss of $133.16 million. Blueprint Medicines collected $36.55 million in revenue during Q2, but reported earnings showed a $159.71 million loss.
What Is ROCE?
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, Blueprint Medicines posted an ROCE of -0.21%.
Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Blueprint Medicines is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.
For Blueprint Medicines, a negative ROCE ratio of -0.21% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.
Upcoming Earnings Estimate
Blueprint Medicines reported Q3 earnings per share at $-2.23/share, which beat analyst predictions of $-2.49/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.